<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117516">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573169</url>
  </required_header>
  <id_info>
    <org_study_id>PREVENTIHS</org_study_id>
    <nct_id>NCT01573169</nct_id>
  </id_info>
  <brief_title>PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients</brief_title>
  <acronym>PREVENTIHS</acronym>
  <official_title>PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with cerebral hemorrhage (ICH) have a high risk of venous thromboembolism.
      Intermittent pneumatic compression combined with elastic stockings have been shown to be
      superior to elastic stockings alone in reducing the rate of asymptomatic deep vein
      thrombosis after ICH in a randomized trial (4.7% vs. 15.9%). Graduated compression stockings
      alone are ineffective in preventing deep vein thrombosis in patients with ischemic or
      hemorrhagic stroke. Less clear is the role of anticoagulation in the prevention of venous
      thromboembolism in patients with ICH because the use of anticoagulants may cause an
      enlargement of the hematoma. In a multicenter, randomized trial, the investigators will
      assess the efficacy and safety of enoxaparin in the prevention of venous thromboembolism in
      patients with spontaneous intracerebral hemorrhage. Enoxaparin (40 mg once daily) or
      standard therapy (graduated compression stockings and/or intermittent pneumatic compression
      and/or early mobilization) will be given subcutaneously for not less than 10 days beginning
      after 72 hours from stroke onset.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    The trial has been momentarily suspended after the randomization of 38 patients due to a lack
    of funding.
  </why_stopped>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic and asymptomatic venous thromboembolism</measure>
    <time_frame>10 days</time_frame>
    <description>Symptomatic venous thromboembolism (deep venous thrombosis and/or pulmonary embolism) and asymptomatic deep venous thrombosis on ultrasound examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleedings</measure>
    <time_frame>90 days</time_frame>
    <description>symptomatic and asymptomatic intra and extracranial bleedings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>90 days</time_frame>
    <description>mortality of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disability</measure>
    <time_frame>90 days</time_frame>
    <description>modified Rankin Scale (mRS) equal to and greater than 3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">406</enrollment>
  <condition>Hemorrhagic Stroke</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Deep Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>low weight molecular heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enoxaparin 0.4 ml subcutaneous per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke</description>
    <arm_group_label>low weight molecular heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization</intervention_name>
    <description>placebo standard therapy</description>
    <arm_group_label>standard therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intracranial spontaneous hemorrhage on brain CT scan

          -  Intracranial hemorrhage during treatment with oral anticoagulants

          -  Bedridden patients (item 6 of NIHSS: motor leg points 3 or 4 or severe ataxia for
             cerebellar hemorrhage).

        Exclusion Criteria:

          -  cerebral hemorrhage due to intracranial vascular malformation

          -  rebleeding on CT scan after 72 hours from stroke (before randomization)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stroke Unit</name>
      <address>
        <city>Perugia</city>
        <zip>06126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Paciaroni M, Agnelli G, Venti M, Alberti A, Acciarresi M, Caso V. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies. J Thromb Haemost. 2011 May;9(5):893-8. doi: 10.1111/j.1538-7836.2011.04241.x.</citation>
    <PMID>21324058</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 20, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Maurizio Paciaroni</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hemorrhagic stroke</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
